Health systems invest aggressively in digital health; why biotech stocks are a dumpster fire

Hospitals nationwide are forming new and larger venture funds to help bankroll the development of software and AI tools. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: 'We must change': Health systems invest more aggressively than ever in digital health By Casey Ross Photo by KEREM YUCEL/AFP via Getty Images Hospitals nationwide are aggressively increasing their digital health investments, signaling their enthusiasm for the future of the sector. Read More STAT+: Biotech stocks are a dumpster fire. An analyst explains what's going on By Adam Feuerstein and Meg Tirrell and Damian Garde Drew Angerer/Getty Images Jared Holz, the health care equity strategist with Oppenheimer, weighs in on the horrible run for the sector in the markets. Read More They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases By Matthew Herper Adobe The U.K. non-profit Protas received $6.8 million to begin its work to accelerate how clinical trials are done and make them far cheaper. Read More Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis ⁠— at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. STAT+: Did veteran drug developer Hal Barron accomplish his mission at GSK? By Matthew Herper STAT Hal Barron was brought in to turn around GSK’s labs at a time when the British drug maker was struggling to develop new medicines. Read More STAT+: Pfizer faces calls to quickly sell more Covid-19 pills to poorer countries By Ed Silverman Pfizer Public Citizen argues inequalities in access to Covid-19 treatments may mirror gaps in vaccine access seen worldwide. Read More Opinion: We all need help working through grief and hardship By Krista Lyn Harrison and Meridith Greene and Anthony Galanos Adobe Medicine and academia reward those who can make hardship invisible. But they, too, need help working through grief. Read More Monday, January 24, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser